Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476413 | 0.88 | AOC3 (0.50) | IGF1RAOC3L3MBTL1MAOBBRD4 | |
| SCHEMBL18529828 | 0.88 | AOC3 (0.50) | IGF1RAOC3L3MBTL1MAOBBRD4 | |
| SCHEMBL2093768 | 0.88 | AOC3 (0.59) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL477338 | 0.86 | AOC3 (0.54) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL27686957 | 0.86 | AOC3 (0.54) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL3470936 | 0.85 | AOC3 (0.50) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL9438783 | 0.83 | LMNA (0.49) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL6442875 | 0.83 | MAPT (0.44) | AOC3MAOBTSHRMAPK1 | |
| SCHEMBL4822561 | 0.82 | AOC3 (0.54) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL5670372 | 0.82 | MAPK1 (0.55) | IGF1RAOC3L3MBTL1MAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983251-B1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LTD (GB) | 2004-06-23 | — | — | EP | disclosed |
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6586431-B1 | Treating drug abuse and drug dependence; nervous system and gastrointestinal disorders | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
| US-6514975-B1 | Tetrazoles as selective agonists for the delta opioid receptor | PFIZER INC | 2003-02-04 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0983251-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | Pfizer Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052929-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| US-5364843-A | Chlorophenyl methoxybenzyl-4-allylpiperazine dihydrochloride | BURROUGHS WELLCOME CO. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0409406-B1 | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-08 | — | — | EP | disclosed |
| US-5124330-A | (E)-ethyl 3-(4-chloro-α-(4-methyl-1-piperazinyl)benzyl)cinnamate used for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS WELLCOME COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | IGF1R 4405/4885AOC3 904/4885L3MBTL1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.